http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 03 Mar 2026 19:03:00 -0500 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Feb+27++Filed+by%3A+Falcione+Aaron/26104907.html si-local-file:///var/storage/secattach/20260303/26104907.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Feb+27++Filed+by%3A+Falcione+Aaron/26104907.html Tue, 03 Mar 2026 19:03:00 -0500 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Feb+27++Filed+by%3A+Falcione+Aaron/26104907.html si-local-file:///var/storage/secattach/20260303/26104907.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Feb+27++Filed+by%3A+Falcione+Aaron/26104907.html Tue, 03 Mar 2026 19:03:00 -0500 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Feb+27++Filed+by%3A+WALSH+MATTHEW+M/26104893.html si-local-file:///var/storage/secattach/20260303/26104893.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Feb+27++Filed+by%3A+WALSH+MATTHEW+M/26104893.html Tue, 03 Mar 2026 19:02:00 -0500 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Feb+27++Filed+by%3A+WALSH+MATTHEW+M/26104893.html si-local-file:///var/storage/secattach/20260303/26104893.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Feb+27++Filed+by%3A+WALSH+MATTHEW+M/26104893.html Tue, 03 Mar 2026 19:02:00 -0500 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Feb+27++Filed+by%3A+Nisita+Vittorio/26104880.html si-local-file:///var/storage/secattach/20260303/26104880.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Feb+27++Filed+by%3A+Nisita+Vittorio/26104880.html Tue, 03 Mar 2026 19:01:00 -0500 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Feb+27++Filed+by%3A+Nisita+Vittorio/26104880.html si-local-file:///var/storage/secattach/20260303/26104880.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Feb+27++Filed+by%3A+Nisita+Vittorio/26104880.html Tue, 03 Mar 2026 19:01:00 -0500 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Feb+27++Filed+by%3A+Stahler+Rachel+A/26104860.html si-local-file:///var/storage/secattach/20260303/26104860.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Feb+27++Filed+by%3A+Stahler+Rachel+A/26104860.html Tue, 03 Mar 2026 18:59:00 -0500 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Feb+27++Filed+by%3A+Stahler+Rachel+A/26104860.html si-local-file:///var/storage/secattach/20260303/26104860.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Feb+27++Filed+by%3A+Stahler+Rachel+A/26104860.html Tue, 03 Mar 2026 18:59:00 -0500 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Feb+27++Filed+by%3A+Weaver+Kirke/26104844.html si-local-file:///var/storage/secattach/20260303/26104844.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Feb+27++Filed+by%3A+Weaver+Kirke/26104844.html Tue, 03 Mar 2026 18:58:00 -0500 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Feb+27++Filed+by%3A+Weaver+Kirke/26104844.html si-local-file:///var/storage/secattach/20260303/26104844.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Feb+27++Filed+by%3A+Weaver+Kirke/26104844.html Tue, 03 Mar 2026 18:58:00 -0500 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Feb+27++Filed+by%3A+Morrissey+Joseph+T.+Jr./26104830.html si-local-file:///var/storage/secattach/20260303/26104830.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Feb+27++Filed+by%3A+Morrissey+Joseph+T.+Jr./26104830.html Tue, 03 Mar 2026 18:57:00 -0500 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Feb+27++Filed+by%3A+Morrissey+Joseph+T.+Jr./26104830.html si-local-file:///var/storage/secattach/20260303/26104830.html http://www.streetinsider.com/SEC+Filings/Form++4++++++++++Organon+%26amp%3B+Co.+++++++++For%3A+Feb+27++Filed+by%3A+Morrissey+Joseph+T.+Jr./26104830.html Tue, 03 Mar 2026 18:57:00 -0500 O.50635033 OGN http://www.streetinsider.com/FDA/Organon%27s+VTAMA+cream+shows+sleep+improvements+in+pediatric+atopic+dermatitis+study/26075984.html <p>Organon & Co. (NYSE: OGN) reported that its VTAMA cream demonstrated improvements in sleep-related measures for pediatric patients with atopic dermatitis in a sub-analysis of Phase 3 trial data.</p> <p>The analysis examined pooled data from 654 children aged 2 to 17 years enrolled in the ADORING 1 and ADORING 2 pivotal trials. Patients received either VTAMA cream or a placebo vehicle once daily for eight weeks.</p> <p>The study measured sleep improvements using Patient-Oriented Eczema Measure (POEM) and Dermatitis Family Impact (DFI) assessment subdomains. Results showed improvements in POEM sleep scores as early as week 1 for children aged 2-6 and 12-17, with http://www.streetinsider.com/FDA/Organon%27s+VTAMA+cream+shows+sleep+improvements+in+pediatric+atopic+dermatitis+study/26075984.html Fri, 27 Feb 2026 08:00:29 -0500 A.06822034 O.20026344 O.50635033 OGN http://www.streetinsider.com/FDA/Organon%27s+VTAMA+cream+shows+sleep+improvements+in+pediatric+atopic+dermatitis+study/26075984.html <p>Organon & Co. (NYSE: OGN) reported that its VTAMA cream demonstrated improvements in sleep-related measures for pediatric patients with atopic dermatitis in a sub-analysis of Phase 3 trial data.</p> <p>The analysis examined pooled data from 654 children aged 2 to 17 years enrolled in the ADORING 1 and ADORING 2 pivotal trials. Patients received either VTAMA cream or a placebo vehicle once daily for eight weeks.</p> <p>The study measured sleep improvements using Patient-Oriented Eczema Measure (POEM) and Dermatitis Family Impact (DFI) assessment subdomains. Results showed improvements in POEM sleep scores as early as week 1 for children aged 2-6 and 12-17, with http://www.streetinsider.com/FDA/Organon%27s+VTAMA+cream+shows+sleep+improvements+in+pediatric+atopic+dermatitis+study/26075984.html Fri, 27 Feb 2026 08:00:29 -0500 A.06822034 O.20026344 O.50635033 OGN http://www.streetinsider.com/FDA/Organon%27s+VTAMA+cream+shows+sleep+improvements+in+pediatric+atopic+dermatitis+study/26075984.html <p>Organon & Co. (NYSE: OGN) reported that its VTAMA cream demonstrated improvements in sleep-related measures for pediatric patients with atopic dermatitis in a sub-analysis of Phase 3 trial data.</p> <p>The analysis examined pooled data from 654 children aged 2 to 17 years enrolled in the ADORING 1 and ADORING 2 pivotal trials. Patients received either VTAMA cream or a placebo vehicle once daily for eight weeks.</p> <p>The study measured sleep improvements using Patient-Oriented Eczema Measure (POEM) and Dermatitis Family Impact (DFI) assessment subdomains. Results showed improvements in POEM sleep scores as early as week 1 for children aged 2-6 and 12-17, with http://www.streetinsider.com/FDA/Organon%27s+VTAMA+cream+shows+sleep+improvements+in+pediatric+atopic+dermatitis+study/26075984.html Fri, 27 Feb 2026 08:00:29 -0500 A.06822034 O.20026344 O.50635033 OGN http://www.streetinsider.com/FDA/Organon%27s+VTAMA+cream+shows+sleep+improvements+in+pediatric+atopic+dermatitis+study/26075984.html <p>Organon & Co. (NYSE: OGN) reported that its VTAMA cream demonstrated improvements in sleep-related measures for pediatric patients with atopic dermatitis in a sub-analysis of Phase 3 trial data.</p> <p>The analysis examined pooled data from 654 children aged 2 to 17 years enrolled in the ADORING 1 and ADORING 2 pivotal trials. Patients received either VTAMA cream or a placebo vehicle once daily for eight weeks.</p> <p>The study measured sleep improvements using Patient-Oriented Eczema Measure (POEM) and Dermatitis Family Impact (DFI) assessment subdomains. Results showed improvements in POEM sleep scores as early as week 1 for children aged 2-6 and 12-17, with http://www.streetinsider.com/FDA/Organon%27s+VTAMA+cream+shows+sleep+improvements+in+pediatric+atopic+dermatitis+study/26075984.html Fri, 27 Feb 2026 08:00:29 -0500 A.06822034 O.20026344 O.50635033 OGN http://www.streetinsider.com/Press+Releases/New+Analysis+of+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Phase+3+Data+Showed+Early+and+Consistent+Improvement+in+Patient-Reported+Sleep+Subdomains+in+Pediatric+Patients+Down+to+2+Years+of+Age+with+A/26075975.html <ul class="bwlistdisc"> <li> Clinically meaningful improvements in sleep scores, as measured by subdomains of the Patient-Oriented Eczema Measure (POEM) and Dermatitis Family Impact (DFI) assessments, were observed as early as week 1 and continued through week 8 </li> </ul> <p> JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present results from a sub-analysis of pooled data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials evaluating VTAMA cream versus vehicle at the 2026 American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting http://www.streetinsider.com/Press+Releases/New+Analysis+of+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Phase+3+Data+Showed+Early+and+Consistent+Improvement+in+Patient-Reported+Sleep+Subdomains+in+Pediatric+Patients+Down+to+2+Years+of+Age+with+A/26075975.html Fri, 27 Feb 2026 08:00:00 -0500 A.06822034 O.20026344 O.50635033 OGN http://www.streetinsider.com/Press+Releases/New+Analysis+of+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Phase+3+Data+Showed+Early+and+Consistent+Improvement+in+Patient-Reported+Sleep+Subdomains+in+Pediatric+Patients+Down+to+2+Years+of+Age+with+A/26075975.html <ul class="bwlistdisc"> <li> Clinically meaningful improvements in sleep scores, as measured by subdomains of the Patient-Oriented Eczema Measure (POEM) and Dermatitis Family Impact (DFI) assessments, were observed as early as week 1 and continued through week 8 </li> </ul> <p> JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present results from a sub-analysis of pooled data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials evaluating VTAMA cream versus vehicle at the 2026 American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting http://www.streetinsider.com/Press+Releases/New+Analysis+of+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Phase+3+Data+Showed+Early+and+Consistent+Improvement+in+Patient-Reported+Sleep+Subdomains+in+Pediatric+Patients+Down+to+2+Years+of+Age+with+A/26075975.html Fri, 27 Feb 2026 08:00:00 -0500 A.06822034 O.20026344 O.50635033 OGN http://www.streetinsider.com/Press+Releases/New+Analysis+of+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Phase+3+Data+Showed+Early+and+Consistent+Improvement+in+Patient-Reported+Sleep+Subdomains+in+Pediatric+Patients+Down+to+2+Years+of+Age+with+A/26075975.html <ul class="bwlistdisc"> <li> Clinically meaningful improvements in sleep scores, as measured by subdomains of the Patient-Oriented Eczema Measure (POEM) and Dermatitis Family Impact (DFI) assessments, were observed as early as week 1 and continued through week 8 </li> </ul> <p> JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present results from a sub-analysis of pooled data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials evaluating VTAMA cream versus vehicle at the 2026 American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting http://www.streetinsider.com/Press+Releases/New+Analysis+of+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Phase+3+Data+Showed+Early+and+Consistent+Improvement+in+Patient-Reported+Sleep+Subdomains+in+Pediatric+Patients+Down+to+2+Years+of+Age+with+A/26075975.html Fri, 27 Feb 2026 08:00:00 -0500 A.06822034 O.20026344 O.50635033 OGN http://www.streetinsider.com/Press+Releases/New+Analysis+of+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Phase+3+Data+Showed+Early+and+Consistent+Improvement+in+Patient-Reported+Sleep+Subdomains+in+Pediatric+Patients+Down+to+2+Years+of+Age+with+A/26075975.html <ul class="bwlistdisc"> <li> Clinically meaningful improvements in sleep scores, as measured by subdomains of the Patient-Oriented Eczema Measure (POEM) and Dermatitis Family Impact (DFI) assessments, were observed as early as week 1 and continued through week 8 </li> </ul> <p> JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present results from a sub-analysis of pooled data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials evaluating VTAMA cream versus vehicle at the 2026 American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting http://www.streetinsider.com/Press+Releases/New+Analysis+of+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Phase+3+Data+Showed+Early+and+Consistent+Improvement+in+Patient-Reported+Sleep+Subdomains+in+Pediatric+Patients+Down+to+2+Years+of+Age+with+A/26075975.html Fri, 27 Feb 2026 08:00:00 -0500 A.06822034 O.20026344 O.50635033 OGN http://www.streetinsider.com/Business+Wire/New+Analysis+of+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Phase+3+Data+Showed+Early+and+Consistent+Improvement+in+Patient-Reported+Sleep+Subdomains+in+Pediatric+Patients+Down+to+2+Years+of+Age+with+A/26075975.html <ul class="bwlistdisc"> <li> Clinically meaningful improvements in sleep scores, as measured by subdomains of the Patient-Oriented Eczema Measure (POEM) and Dermatitis Family Impact (DFI) assessments, were observed as early as week 1 and continued through week 8 </li> </ul> <p> JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present results from a sub-analysis of pooled data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials evaluating VTAMA cream versus vehicle at the 2026 American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting http://www.streetinsider.com/Business+Wire/New+Analysis+of+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Phase+3+Data+Showed+Early+and+Consistent+Improvement+in+Patient-Reported+Sleep+Subdomains+in+Pediatric+Patients+Down+to+2+Years+of+Age+with+A/26075975.html Fri, 27 Feb 2026 08:00:00 -0500 A.06822034 O.20026344 O.50635033 OGN http://www.streetinsider.com/Business+Wire/New+Analysis+of+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Phase+3+Data+Showed+Early+and+Consistent+Improvement+in+Patient-Reported+Sleep+Subdomains+in+Pediatric+Patients+Down+to+2+Years+of+Age+with+A/26075975.html <ul class="bwlistdisc"> <li> Clinically meaningful improvements in sleep scores, as measured by subdomains of the Patient-Oriented Eczema Measure (POEM) and Dermatitis Family Impact (DFI) assessments, were observed as early as week 1 and continued through week 8 </li> </ul> <p> JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present results from a sub-analysis of pooled data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials evaluating VTAMA cream versus vehicle at the 2026 American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting http://www.streetinsider.com/Business+Wire/New+Analysis+of+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Phase+3+Data+Showed+Early+and+Consistent+Improvement+in+Patient-Reported+Sleep+Subdomains+in+Pediatric+Patients+Down+to+2+Years+of+Age+with+A/26075975.html Fri, 27 Feb 2026 08:00:00 -0500 A.06822034 O.20026344 O.50635033 OGN http://www.streetinsider.com/Business+Wire/New+Analysis+of+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Phase+3+Data+Showed+Early+and+Consistent+Improvement+in+Patient-Reported+Sleep+Subdomains+in+Pediatric+Patients+Down+to+2+Years+of+Age+with+A/26075975.html <ul class="bwlistdisc"> <li> Clinically meaningful improvements in sleep scores, as measured by subdomains of the Patient-Oriented Eczema Measure (POEM) and Dermatitis Family Impact (DFI) assessments, were observed as early as week 1 and continued through week 8 </li> </ul> <p> JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present results from a sub-analysis of pooled data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials evaluating VTAMA cream versus vehicle at the 2026 American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting http://www.streetinsider.com/Business+Wire/New+Analysis+of+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Phase+3+Data+Showed+Early+and+Consistent+Improvement+in+Patient-Reported+Sleep+Subdomains+in+Pediatric+Patients+Down+to+2+Years+of+Age+with+A/26075975.html Fri, 27 Feb 2026 08:00:00 -0500 A.06822034 O.20026344 O.50635033 OGN http://www.streetinsider.com/Business+Wire/New+Analysis+of+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Phase+3+Data+Showed+Early+and+Consistent+Improvement+in+Patient-Reported+Sleep+Subdomains+in+Pediatric+Patients+Down+to+2+Years+of+Age+with+A/26075975.html <ul class="bwlistdisc"> <li> Clinically meaningful improvements in sleep scores, as measured by subdomains of the Patient-Oriented Eczema Measure (POEM) and Dermatitis Family Impact (DFI) assessments, were observed as early as week 1 and continued through week 8 </li> </ul> <p> JERSEY CITY, N.J.--(BUSINESS WIRE)-- Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, will present results from a sub-analysis of pooled data from the Phase 3 ADORING 1 and ADORING 2 pivotal trials evaluating VTAMA cream versus vehicle at the 2026 American Academy of Allergy, Asthma &amp; Immunology (AAAAI) Annual Meeting http://www.streetinsider.com/Business+Wire/New+Analysis+of+Organon%E2%80%99s+VTAMA%C2%AE+%28tapinarof%29+cream%2C+1%25%2C+Phase+3+Data+Showed+Early+and+Consistent+Improvement+in+Patient-Reported+Sleep+Subdomains+in+Pediatric+Patients+Down+to+2+Years+of+Age+with+A/26075975.html Fri, 27 Feb 2026 08:00:00 -0500 A.06822034 O.20026344 O.50635033 OGN http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Organon+%26amp%3B+Co.+++++++++For%3A+Dec+31/26051993.html si-local-file:///var/storage/secattach/20260224/26051993.html http://www.streetinsider.com/SEC+Filings/Form++10-K+++++++Organon+%26amp%3B+Co.+++++++++For%3A+Dec+31/26051993.html Tue, 24 Feb 2026 16:25:00 -0500 O.50635033 OGN